Published in J Neural Transm (Vienna) on March 01, 2003
Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics (2008) 0.94
Health-related quality of life as an outcome variable in Parkinson's disease. Ther Adv Neurol Disord (2012) 0.92
The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm (Vienna) (2010) 0.90
Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data. J Neurol (2008) 0.88
Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo). Neuropsychiatr Dis Treat (2010) 0.79
One-year open-label study of entacapone in patients with advanced Parkinson disease. J Clin Neurol (2007) 0.75
Prescription of drugs during pregnancy in France. Lancet (2000) 4.12
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther (2011) 3.16
Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord (1994) 2.61
Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain (2000) 2.06
[Neurology and the primary health care system]. Neurologia (1994) 2.02
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther (2015) 2.00
Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther (2015) 1.99
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database. Pharmacoepidemiol Drug Saf (2006) 1.96
Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord (2000) 1.77
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol (2013) 1.74
[Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. Rev Clin Esp (1998) 1.70
Cardiovascular reflexes in patients with vascular headache. Cephalalgia (1992) 1.42
Dementia paralytica: deterioration from communicating hydrocephalus. J Neurol Neurosurg Psychiatry (1979) 1.42
Estimation of premorbid intelligence in Spanish people with the Word Accentuation Test and its application to the diagnosis of dementia. Brain Cogn (1997) 1.40
Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. J Neurol Sci (1993) 1.39
[Arnold-Chiari malformation with multiple paroxysmal manifestations induced by coughing]. Neurologia (1992) 1.36
Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain (2000) 1.36
Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry (1997) 1.36
Water drinking and the heart. Lancet (1999) 1.34
Antivertigo medications and drug-induced vertigo. A pharmacological review. Drugs (1995) 1.33
Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals. Br J Clin Pharmacol (2002) 1.27
Sleep attacks and Parkinson's disease treatment. Lancet (2000) 1.25
Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine. Clin Neuropharmacol (1986) 1.25
The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients. Brain (1997) 1.23
Long-term prognosis of ischemic stroke in young adults. Study of 272 cases. J Neurol (2004) 1.23
Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Eur J Clin Invest (1990) 1.18
Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol (2000) 1.18
Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population? Neurology (2007) 1.15
Effects of yohimbine on submaxillary salivation in dogs. Br J Pharmacol (1989) 1.15
Vascular dementia. A clinicopathological study. J Neurol Sci (1990) 1.15
Supplementary and primary sensory motor area activity in Parkinson's disease. Regional cerebral blood flow changes during finger movements and effects of apomorphine. Arch Neurol (1992) 1.13
Causes of ischemic stroke in young adults, and evolution of the etiological diagnosis over the long term. Eur Neurol (2007) 1.12
Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother (1999) 1.11
Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain (1989) 1.09
Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation. Brain (2007) 1.09
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry (2004) 1.09
Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci (1992) 1.09
Intravenous immunoglobulin therapy in sensory neuropathy associated with Sjögren's syndrome. J Neurol Neurosurg Psychiatry (1996) 1.08
Neuroimaging in the evaluation of patients with non-acute headache. Cephalalgia (2005) 1.08
Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol (2009) 1.08
[Brain dynamics according to Justo Gonzalo]. Neurologia (2004) 1.08
Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol (2007) 1.07
Effect of ropinirole on sleep onset: a randomized, placebo-controlled study in healthy volunteers. Neurology (2002) 1.07
Yohimbine increases human salivary secretion. Br J Clin Pharmacol (1989) 1.07
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract (2006) 1.07
[Sneddon's syndrome: its clinical characteristics and etiopathogenic factors]. Rev Clin Esp (1992) 1.07
The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology (2001) 1.05
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry (2001) 1.05
Clinical-CT correlations in TIA, RIND, and strokes with minimum residuum. Stroke (1984) 1.04
Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther (1994) 1.04
Nummular headache secondary to an intracranial mass lesion. Cephalalgia (2007) 1.04
Lipolytic effects of conventional beta 3-adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative beta 4-adrenoceptor. Br J Pharmacol (1997) 1.03
The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther (1992) 1.03
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain (1998) 1.03
Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls. J Med Genet (2007) 1.02
Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord (2001) 1.01
Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord (1992) 1.01
Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry (1991) 1.01
The screening of mild dementia with a shortened Spanish version of the "Informant Questionnaire on Cognitive Decline in the Elderly". Alzheimer Dis Assoc Disord (1995) 1.01
Odorous urine in man after asparagus. Br J Clin Pharmacol (1989) 1.00
Application of a Spanish version of the "Informant Questionnaire on Cognitive Decline in the Elderly" in the clinical assessment of dementia. Alzheimer Dis Assoc Disord (1997) 1.00
Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging (2001) 0.99
Tabetic lightning pains: high-dosage intravenous penicillin versus carbamazepine therapy. Eur Neurol (1981) 0.99
Yohimbine increases submaxillary kallikrein release into the saliva in dogs: evidence for alpha 2-adrenoceptor-mediated inhibition of cholinergic pathways. Br J Pharmacol (1991) 0.99
Ambulatory blood pressure in patients with Parkinson's disease without and with orthostatic hypotension. Clin Auton Res (1992) 0.99
[Drug-induced hiccup: a review of the France pharmacologic vigilance database]. Therapie (1999) 0.99
Manic behaviour induced by deep-brain stimulation in Parkinson's disease: evidence of substantia nigra implication? J Neurol Neurosurg Psychiatry (2006) 0.98
Aortic dissection presenting with neurologic signs. N Engl J Med (1988) 0.98
Screening of dementia in community-dwelling elderly through informant report. Int J Geriatr Psychiatry (1997) 0.98
Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig (2005) 0.98
Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course. Br J Clin Pharmacol (2007) 0.97
Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. J Neurol Neurosurg Psychiatry (1994) 0.97
Hematocrit and clinical outcome in acute cerebral infarction. Stroke (1988) 0.97
Enzymatic synthesis of penicillins. J Antibiot (Tokyo) (1988) 0.96
[3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain. Neuroscience (2003) 0.96
[Drug vigilance: opinion survey among residents of a university hospital]. Therapie (1995) 0.96
Abnormalities of Bell's phenomenon in amyotrophic lateral sclerosis: a clinical and electrophysiological evaluation. J Neurol Neurosurg Psychiatry (1978) 0.95
Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator® ) withdrawal in France. J Clin Pharm Ther (2013) 0.94
L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neuropharmacol (1999) 0.94
Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet (2005) 0.94
"Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol (2005) 0.94
Differential distribution of metabotropic glutamate receptor subtype mRNAs in the thalamus of the rat. Brain Res (2000) 0.92
Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. Addiction (2004) 0.92
Overweight after deep brain stimulation of the subthalamic nucleus in Parkinson disease: long term follow-up. J Neurol Neurosurg Psychiatry (2008) 0.92
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. J Neurosci Methods (2001) 0.92
Sensory ataxic hemiparesis in thalamic hemorrhage. Stroke (1990) 0.92
Drug-induced myoclonus: a French pharmacovigilance database study. Neurophysiol Clin (2007) 0.91
Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther (2004) 0.91
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord (1994) 0.91
Alpha-adrenolytic properties of bromocriptine in dogs. Arch Int Pharmacodyn Ther (1982) 0.91
Clinicopathological correlation in symptomatic dystonia. Adv Neurol (1988) 0.91
[Spontaneous peritonitis caused by ascitic fluid with Candida albicans]. Rev Clin Esp (1997) 0.91
[Cerebral hemodynamics and clinical pharmacology in Parkinson disease]. Therapie (1988) 0.90
Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res (1991) 0.90
Apomorphine test in parkinsonian syndromes. Lancet (1990) 0.90
[Drug-induced alopecia: review of the literature]. Therapie (1995) 0.90
Non-adjuvanted 2009 influenza A (H1N1)v vaccine in pregnant women: the results of a French prospective descriptive study. Vaccine (2011) 0.90
Photosensitivity to ketoprofen: mechanisms and pharmacoepidemiological data. Drug Saf (2000) 0.90